This study examines the development and optimization of matrix tablets containing danuglipron, a GLP-1 receptor agonist, over a wide range of drug loadings and extended drug release rates. Hypromellose was chosen as the release controlling polymer as it enabled tunability. Formulation components and levels were explored which provided optimal manufacturability for active tablet strength ranging from 10 mg to 400 mg. Matrix tablets containing microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate demonstrated optimal tablet hardness, suitable friability and adequate powder flow of the blends with no evidence of tablet punch sticking over the drug loading range. Direct compression was selected as the preferred manufacturing method due to its superior hardness profile and simplicity. Drug release was controlled through a combination of hypromellose type 2208 (100 mPa.s and 4000 mPa.s), while maintaining the total polymer content at 30% w/w in the tablet. This study demonstrates that the ratio of two hypromellose grades can be adjusted to tune the drug release rate to 4 to > 24-hours over 4% to 40% active drug loading range. Mechanistic studies show that tablets both swell and erode when hydrated with higher content of the 4000 mPa.s hypromellose leading to increased swelling, while those with higher 100 mPa.s polymer content resulted in greater erosion. The Korsmeyer–Peppas model was applied to analyze the release kinetics, revealing a combined effect of erosion and diffusion mechanisms for all the formulations studied. The release mechanism was the same regardless of danuglipron drug loading, suggesting the in vivo performance would be consistent for all tablet strengths. The in vitro release study confirmed the effectiveness of the matrix design for a wide range of tablet strengths, showcasing its potential for enhancing the pharmacokinetic profiles for a more convenient once daily (QD) drug delivery system.